Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant IFN-α in Curatively Resected Hepatocellular Carcinoma
NCT00149565Phase 3Completed
- Sponsor
- National Health Research Institutes
- Start
- Oct 1997
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon alfa-2b in hepatocellular carcinoma (HCC) (2 arms), sponsored by National Health Research Institutes. Primary endpoints: Disease-Free Survival at 5 years, Overall Survival at 5 years and 1 more. Started Oct 1997; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00149565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149565.